Alector (Alector) Operating Cash Flow per Share : $-2.27 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alector Operating Cash Flow per Share?

Alector's operating cash flow per share for the three months ended in Mar. 2024 was $-0.65. Alector's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.27.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Alector's Operating Cash Flow per Share or its related term are showing as below:

ALEC' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -85 Med: -0.8 Max: 46.5
Current: -0.8

During the past 8 years, Alector's highest 3-Year average Operating Cash Flow per Share Growth Rate was 46.50% per year. The lowest was -85.00% per year. And the median was -0.80% per year.

ALEC's 3-Year OCF Growth Rate is ranked worse than
56.29% of 1240 companies
in the Biotechnology industry
Industry Median: 3.55 vs ALEC: -0.80

Alector Operating Cash Flow per Share Historical Data

The historical data trend for Alector's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Operating Cash Flow per Share Chart

Alector Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.61

-2.14

3.71

-0.25

-2.20

Alector Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.58	-0.52	-0.56	-0.55	-0.65

Competitive Comparison of Alector's Operating Cash Flow per Share

For the Biotechnology subindustry, Alector's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alector's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Alector's Price-to-Operating-Cash-Flow falls into.

Alector Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Alector's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-184.162	/	83.734
	=	-2.20

Alector's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-61.346	/	93.810
	=	-0.65

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.27

Alector Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Alector's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alector (Alector) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0Z2:Germany

Address

131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080

Website

https://www.alector.com

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Executives

Sara Kenkare-mitra	officer: President and Head of R&D	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano	officer: Chief Medical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal	director, officer: Chief Executive Officer	C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso	officer: Chief Financial Officer	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Terrance Mcguire	director, 10 percent owner	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Polaris Venture Management Co. Vi, L.l.c.	10 percent owner	ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Tillman U. Gerngross	director	C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr	director	C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner	director	C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Robert King	officer: Chief Development Officer	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman	officer: President and COO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080